沃比医疗携手Brainomix为中国卒中临床提供AI卒中成像解决方案

日期:2021-09-25 17:08Wallaby Medical

2021年8月26日,上海—日前,沃比医疗与Brainomix Limited(简称“Brainomix”)宣布签署大中华区的战略合作协议。沃比医疗总部位于上海,作为一家专注于神经介入领域的医疗科技公司,其致力于自主研发和独立制造脑卒中治疗的前沿产品,旨在为全球卒中临床提供国际一流品质的卒中解决方案,从而挽救更多脑卒中患者。国际领先的人工智能医学影像公司Brainomix, 其总部位于英国, 致力于依托前沿的AI人工智能影像评估技术为卒中临床提供快速且精准的诊断决策,以改善脑血管病患者的疗效。Brainomix公司的e-Stroke软件,是沃比医疗向中国卒中临床提供脑血管病全流程解决方案中至关重要的一环。

image.png

image.png

在中国,每年超过179万人因脑卒中而死亡1,脑卒中已成为中国成年人致残的主要原因之一。基于双方签署的战略合作协议,沃比医疗将加速e-Stroke人工智能影像软件在中国卒中中心的临床应用,并与Brainomix携手为中国卒中临床提供脑血管病诊疗一体化的全流程解决方案,从而改善中国脑卒中患者预后,降低致残和致死率,助力百万减残。

image.png


Brainomixe-Stroke软件是一个结合AI智能算法,支持扫描和影像结果评估的软件平台,通过实时分析和解读脑部的扫描结果,为整个卒中诊疗网络中的临床医生提供支持和指导,为脑卒中患者的治疗和转移决策提供建议,确保更多卒中患者能够在正确时间和正确地点获得正确治疗。e-Stroke平台由三个模块(e-ASPECTSe-CTAe-CTP)组成,支持所有基于成像的需求,并提供从简单成像到高阶评估的全网络一体化的解决方案。


image.png

目前全球超过30个国家,共计280家卒中中心应用Brainomixe-Stroke软件平台进行卒中AI影像评估和决策指导,每月超过10,000位脑卒中患者获益于该软件平台,累计超过50次扫描。

image.png

目前e-Stroke软件已获得中国脑血管病临床的初步认可。首都医科大学宣武医院焦力群博士的团队表示:“Brainomixe-Stroke平台是一个强大且有效的AI诊断软件,可以在脑卒中患者的脑部CT扫描基础上评估早期缺血迹象。它有助于识别适合进行血栓切除术的患者,并改善患者手术结果。Brainomix AI分析和血栓切除术是完美组合,两者结合可以为脑卒中患者提供最佳治疗。

image.png

沃比医疗首席执行官兼联合创始人Michael Alper表示:因为我们致力于改善脑卒中患者的疗效,所以我们很清楚术前诊断快速和准确的重要性。通过这一合作伙伴关系,沃比医疗将为中国卒中临床带来更全面的一体化AI卒中成像软件解决方案,助力中国临床医生做出快速准确的治疗决策。我们很高兴能够帮助医生尽可能地优化患者的手术结果

Brainomix首席执行官兼联合创始人Michalis Papadakis博士称:我们很高兴能与沃比医疗达成合作伙伴的关系,他们在中国已有的众多成功案例展现出沃比医疗的实力,并体现出其为临床专家提供前沿解决方案的决心。我们认为中国蕴藏着巨大的潜力,我们十分期待与沃比医疗的合作,使得我们创新研发的e-Stroke软件平台深入中国更多卒中医院和网络的使用,e-Stroke平台期待帮助更多中国脑卒中患者获得挽救生命的治疗。

1.         Johnson et al. Lancet Neurol (2019).

 

关于沃比医疗

 沃比医疗是一家专注于神经介入领域的医疗科技公司,致力于成为全球挽救中风患者生命最多的医疗科技公司。Wallaby Medical创建于201512月,上海沃比创建于20167月,公司总部和生产基地位于上海医谷,美国设有研发中心。公司主要研发和生产用于治疗脑血管疾病的创新产品。沃比医疗的产品包括Avenir机械解脱弹簧圈和Esperance®远端通路导管。Avenir机械解脱弹簧圈系统是一种具有技术差异化的神经栓塞弹簧圈系统,用于治疗颅内动脉瘤和其他神经血管畸形;Esperance®远端通路导管已在中国获批上市,用于缺血性卒中和出血性卒中治疗手术。此外,沃比医疗正在研发全方位的神经血管产品。沃比医疗的产品已在20多个国家和地区实现商业化应用。 

更多信息请访问www.wallabymedical.com

 

关于Brainomix Limited

Brainomix是一家总部位于牛津,为实现更好地进行治疗决策而致力于创建AI赋能解决方案,以实现精准医疗的公司。Brainomix成立于2010年,是牛津大学的衍生公司,其e-Stroke平台为临床医生提供全面的卒中成像解决方案,帮助解读图像并为疑似中风患者提供更快、更准确的治疗决策。

如欲了解更多关于Brainomix及技术的信息,请访问 www.brainomix.com,并在Twitter、Linkedln 和 Facebook 上关注我们。


 

SHANGHAI, CHINA – August 26, 2021 -  Wallaby Medical (“Wallaby”), a rapidly growing medical device company focused on developing and commercializing medical device products for treating stroke, and Brainomix Limited (“Brainomix”), a UK-headquartered company that specializes in the creation of AI-powered imaging biomarkers and software solutions that enable precision medicine for better treatment decisions, announced the signing of a new distribution agreement. As part of the agreement, Wallaby will distribute Brainomix’s e-Stroke software to stroke centres across Greater China.

 

Stroke accounts for over 1.79 million deaths1 annually in China and is one of the leading causes of adult disability. Wallaby’s mission is to become the medical technology company which saves the greatest number of lives of people affected by stroke, and Brainomix’s leading-edge AI diagnostic tool is an important addition to the full range of products and solutions that Wallaby provides to physicians treating stroke. “We are dedicated to improving stroke patient care and understand the importance of speed and precision. With this partnership, Wallaby will bring comprehensive AI stroke imaging software solutions to support fast and accurate treatment decisions in Chinese hospitals. We are excited to enable our physician community to deliver the best possible outcome for their patients.” said Michael Alper, CEO, Wallaby Medical.

 

Brainomix’s e-Stroke is an AI-powered software platform that supports physicians across a stroke network by providing real-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time. Consisting of three modules – e-ASPECTS, e-CTA and e-CTP – the e-Stroke platform can support comprehensive imaging-based needs, enabling full network solutions, from simple imaging to more advanced assessments.

 

e-Stroke has already received the support of Chinese physicians.  Dr. JIAO Liqun’s team at Xuanwu Hospital, Capital Medical University in Beijing commented “e-Stroke platform is a powerful and effective AI diagnostic software to assess early ischemic signs on stroke patients’ plain CT brain scans. It helps to identify appropriate patients for thrombectomy and leads to improved patient outcomes.”  Brainomix AI analysis and thrombectomy are the “perfect couple” to combine together for better treatment for stroke patients.

 

“We are excited to launch this partnership with Wallaby, who have demonstrated a strong track record of success in China, with a commitment to providing best-in-class solutions for their customers. We see tremendous potential in China and look forward to working with Wallaby to deliver our innovative e-Stroke platform to hospitals and networks as a way of expanding access for more Chinese stroke patients to life-saving treatments,” said Dr. Michalis Papadakis, CEO and co-founder of Brainomix. 

 

About Wallaby Medical

 

Wallaby Medical focuses on developing and commercializing medical device products for treating stroke. Wallaby’s products include the Avenir® Coil System which is a technically differentiated neuro embolic coil system for treating intracranial aneurysms and other neurovascular abnormalities, and the Esperance DAC catheter, which is already approved in China, for ischemic stroke and hemorrhagic stroke treatment procedures. In addition, Wallaby has a full range of neurovascular products under development. Wallaby’s products are commercialized in over 20 countries and regions. For more information, visit www.wallabymedical.com.


About Brainomix Limited

 

Brainomix is an Oxford-based company specializing in the creation of AI-powered software solutions to enable precision medicine for better treatment decisions. Founded in 2010 as a spin-out of the University of Oxford, its e-Stroke Suite provides clinicians with comprehensive stroke imaging solution, helping to interpret images and facilitating faster, more confident treatment decisions for patients with suspected stroke. To learn more about Brainomix and its technology visit www.brainomix.com, and follow us on Twitter, Linkedln and Facebook.

 

1.     Johnson et al. Lancet Neurol (2019).

©2020 Wallaby Medical保留所有权利

沪ICP备19039499号-1